Téblick, Laura
Lipovac, Marijana
Bell, Margo
De Smet, Annemie
De Meester, Ingrid
Delputte, Peter
Vorsters, Alex
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (11PJK24N)
Universiteit Antwerpen (44754)
European Research Council (101040588)
Article History
Received: 30 November 2023
Accepted: 18 June 2024
First Online: 23 June 2024
Competing interests
: Alex Vorsters is a cofounder and former board member of Novosanis (Subsidiary of OraSure Technologies Inc., Wijnegem, Belgium), a spin‐ off company of the University of Antwerp and was a minority shareholder until January 2019. The University of Antwerp received grants from Merck, GSK, Hologic, Abbott, Roche, and Cepheid to support the HPV Prevention and Control Board. The University of Antwerp received a project grant and honoraria fee for lectures, presentations, and speaker bureaus from Merck. Other authors declare that they have no conflict of interest.